What is NUVL's current stock price?

As of now, NUVL is trading at $108.00, with a daily change of +1.30%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

NUVL Stock Analysis & IQ Rating | Nuvalent

NUVL

Nuvalent

$108.00

+$1.14 | +1.30%

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$112.88

MKT CAP

$8.34B

52W Low

$55.54

VOL

$42.55K

P/E Ratio

N/A

AVG VOL

$728.30K

RSI

60.12

TREND

Uptrend

NUVL Stock IQ

Login to see Nuvalent (NUVL) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

NUVL Target Price

Login to display

Strengths

NUVL Rewards

Upgraded on attractively valued

NUVL Rewards

Outperform the market

NUVL Price Performance

$93.35 (+15.69%)

$82.22 (+31.35%)

$85.45 (+26.39%)

$83.45 (+29.42%)

1year

6month

3month

1month

NUVL Risk Level

NUVL has Fair risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Risks Indicators

Beta greater than 1.0

Fair

LOW

HIGH

NUVL Analysts Opinion

NUVL overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

NUVL Analysts Opinion

NUVL Analysts opinion is positive and also has improved from the past 3 months

NUVL Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential

100%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

NUVL Street Sentiment

NUVL Street Sentiment is extremely bullish and have positive views on the near-term outlook

NUVL Performance Sentiment

Sentiments overview associated with NUVL events and the stock performance.

100%

0%

Positive

Negative

27 out of 27
events present

0 out of 27
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Login to display

Support
Price

$106.90

Resistance
Price

$91.92

Current Price Range

$109.87

Show methods +

NUVL Latest Analysis +

Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference. CAMBRIDGE Mass. Nov. 26 2025 /PRNewswire/ -- Nuvalent Inc. (Nasdaq: NUVL) a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer today announced that James Porter Ph.D. Chief Executive Officer and...

Wed Nov 26, 2025

$109.06 | -0.73%

Activity

Truist Securities Initiates Coverage of Nuvalent (NUVL) with Buy Recommendation. Fintel reports that on November 24 2025 Truist Securities initiated coverage of Nuvalent (NasdaqGS:NUVL) with a Buy recommendation. Analyst Price Forecast Suggests 21.00% Upside

Tue Nov 25, 2025

$109.87 | +0.30%

Rating

Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders. CAMBRIDGE Mass. Nov. 24 2025 /PRNewswire/ -- Nuvalent Inc. (Nasdaq: NUVL) a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer today announced the closing of its previously announced underwritten...

Mon Nov 24, 2025

$109.53 | +3.45%

Activity

Nuvalents NDA For Zidesamtinib In ROS1-Positive NSCLC Accepted By FDA . (RTTNews) - Nuvalent Inc. (NUVL) announced that the United States Food and Drug Administration has accepted for filing its New Drug Application (NDA) for zidesamtinib an investigational ROS1-selective inhibitor for the treatment of adult patients with locally advanced or metastatic ROS

Thu Nov 20, 2025

$108.01 | +0.82%

Activity

FDA Accepts Nuvalents NDA For Zidesamtinib In ROS1-Positive Non-Small Cell Lung Cancer . (RTTNews) - Nuvalent Inc. (NUVL) announced that its New Drug Application seeking approval of Zidesamtinib for treating adult patients with advanced ROS1-positive non-small cell lung cancer has been accepted for review by the FDA and assigned a decision date of September 18 2026.

Thu Nov 20, 2025

$108.01 | +0.82%

Activity

FDA accepts NDA for Nuvalents zidesamtinib for non-small cell lung cancer.

Wed Nov 19, 2025

$107.13 | +2.77%

Activity

Guggenheim Maintains Nuvalent (NUVL) Buy Recommendation. Fintel reports that on November 18 2025 Guggenheim maintained coverage of Nuvalent (NasdaqGS:NUVL) with a Buy recommendation. Analyst Price Forecast Suggests 18.62% Upside

Wed Nov 19, 2025

$107.13 | +2.77%

Rating

Baird Maintains Nuvalent (NUVL) Outperform Recommendation. Fintel reports that on November 18 2025 Baird maintained coverage of Nuvalent (NasdaqGS:NUVL) with a Outperform recommendation. Analyst Price Forecast Suggests 18.62% Upside

Wed Nov 19, 2025

$107.13 | +2.77%

Potential

Rating

Goldman Sachs Maintains Nuvalent (NUVL) Buy Recommendation. Fintel reports that on November 18 2025 Goldman Sachs maintained coverage of Nuvalent (NasdaqGS:NUVL) with a Buy recommendation. Analyst Price Forecast Suggests 18.62% Upside

Wed Nov 19, 2025

$107.13 | +2.77%

Rating

HC Wainwright & Co. Maintains Nuvalent (NUVL) Buy Recommendation. Fintel reports that on November 17 2025 HC Wainwright &. Co. maintained coverage of Nuvalent (NasdaqGS:NUVL) with a Buy recommendation. Analyst Price Forecast Suggests 18.48% Upside

Tue Nov 18, 2025

$104.24 | -3.48%

Rating

FAQ About NUVL Stock Insights

What is NUVL current stock price?

What are NUVL stock strengths?

What is NUVL Risk Level?

What is NUVL market cap and volume?

What is NUVL current Stock IQ?

Should I buy NUVL stock right now?

Is NUVL a Strong Buy right now?

What does a 'Strong Buy' rating mean for NUVL?

What does a 'Strong Sell' rating mean for NUVL?

What factors influence NUVL's Stock IQ?

Explore our NUVL Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored NUVL Stock Strategies
Effective Risk Management

FIND US ON

Receive our NUVL Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

NUVL

Nuvalent

Current Price

$108.00

+$1.14 | +1.30%

52W High

$112.88

MKT CAP

$8.34B

52W Low

$55.54

VOL

$42.55K

P/E Ratio

N/A

AVG VOL

$728.30K

RSI

60.12

TREND

Uptrend

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

NUVL Rewards

Upgraded on attractively valued

NUVL Rewards

Outperform the market

NUVL Price Performance

$93.35 (+15.69%)

$82.22 (+31.35%)

$85.45 (+26.39%)

$83.45 (+29.42%)

1year

6month

3month

1month

NUVL Analysts Opinion

NUVL Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

NUVL Analysts Opinion

NUVL Analysts opinion is positive and also has improved from the past 3 months

NUVL Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential

100%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

NUVL Street Sentiment

NUVL Street Sentiment is extremely bullish and have positive views on the near-term outlook

NUVL Risk Level

NUVL has Fair risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Risks Indicators

Beta greater than 1.0

Fair

LOW

HIGH

NUVL Performance Sentiment

Sentiments overview associated with NUVL events and the stock performance.

100%

0%

Positive

Negative

27 out of 27
events present

0 out of 27
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Login to display

Support
Price

$106.90

Resistance
Price

$91.92

Current Price Range

$109.87

Show methods +

NUVL Stock IQ

Login to unlock Nuvalent (NUVL) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

NUVL Latest Analysis

Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference. CAMBRIDGE Mass. Nov. 26 2025 /PRNewswire/ -- Nuvalent Inc. (Nasdaq: NUVL) a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer today announced that James Porter Ph.D. Chief Executive Officer and...

Wed Nov 26, 2025

$109.06 | -0.73%

Activity

Truist Securities Initiates Coverage of Nuvalent (NUVL) with Buy Recommendation. Fintel reports that on November 24 2025 Truist Securities initiated coverage of Nuvalent (NasdaqGS:NUVL) with a Buy recommendation. Analyst Price Forecast Suggests 21.00% Upside

Tue Nov 25, 2025

$109.87 | +0.30%

Rating

Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders. CAMBRIDGE Mass. Nov. 24 2025 /PRNewswire/ -- Nuvalent Inc. (Nasdaq: NUVL) a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer today announced the closing of its previously announced underwritten...

Mon Nov 24, 2025

$109.53 | +3.45%

Activity

Nuvalents NDA For Zidesamtinib In ROS1-Positive NSCLC Accepted By FDA . (RTTNews) - Nuvalent Inc. (NUVL) announced that the United States Food and Drug Administration has accepted for filing its New Drug Application (NDA) for zidesamtinib an investigational ROS1-selective inhibitor for the treatment of adult patients with locally advanced or metastatic ROS

Thu Nov 20, 2025

$108.01 | +0.82%

Activity

FDA Accepts Nuvalents NDA For Zidesamtinib In ROS1-Positive Non-Small Cell Lung Cancer . (RTTNews) - Nuvalent Inc. (NUVL) announced that its New Drug Application seeking approval of Zidesamtinib for treating adult patients with advanced ROS1-positive non-small cell lung cancer has been accepted for review by the FDA and assigned a decision date of September 18 2026.

Thu Nov 20, 2025

$108.01 | +0.82%

Activity

FDA accepts NDA for Nuvalents zidesamtinib for non-small cell lung cancer.

Wed Nov 19, 2025

$107.13 | +2.77%

Activity

Guggenheim Maintains Nuvalent (NUVL) Buy Recommendation. Fintel reports that on November 18 2025 Guggenheim maintained coverage of Nuvalent (NasdaqGS:NUVL) with a Buy recommendation. Analyst Price Forecast Suggests 18.62% Upside

Wed Nov 19, 2025

$107.13 | +2.77%

Rating

Baird Maintains Nuvalent (NUVL) Outperform Recommendation. Fintel reports that on November 18 2025 Baird maintained coverage of Nuvalent (NasdaqGS:NUVL) with a Outperform recommendation. Analyst Price Forecast Suggests 18.62% Upside

Wed Nov 19, 2025

$107.13 | +2.77%

Potential

Rating

Goldman Sachs Maintains Nuvalent (NUVL) Buy Recommendation. Fintel reports that on November 18 2025 Goldman Sachs maintained coverage of Nuvalent (NasdaqGS:NUVL) with a Buy recommendation. Analyst Price Forecast Suggests 18.62% Upside

Wed Nov 19, 2025

$107.13 | +2.77%

Rating

HC Wainwright & Co. Maintains Nuvalent (NUVL) Buy Recommendation. Fintel reports that on November 17 2025 HC Wainwright &. Co. maintained coverage of Nuvalent (NasdaqGS:NUVL) with a Buy recommendation. Analyst Price Forecast Suggests 18.48% Upside

Tue Nov 18, 2025

$104.24 | -3.48%

Rating

Discover NUVL Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of NUVL. We're here to help you make informed investment decisions today.

FIND US ON

Receive our NUVL Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

NUVL Stock trends

NUVL Stock performance

NUVL Stock analysis

NUVL investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing NUVL

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing NUVL

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

NUVL Stock Analysis & IQ Rating | Nuvalent

NUVL Stock IQ

NUVL Target Price

NUVL Risk Level

NUVL Analysts Opinion

NUVL Street Sentiment

NUVL Performance Sentiment

Technical Price Levels

Explore our NUVL Stock insights

Receive our NUVL Daily Alerts

NUVL Street Sentiment

NUVL Risk Level

Technical Price Levels

Discover NUVL Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of NUVL. We're here to help you make informed investment decisions today.

Receive our NUVL Daily Alerts

NUVL Runner Alarm